<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1791">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04805970</url>
  </required_header>
  <id_info>
    <org_study_id>1605203</org_study_id>
    <nct_id>NCT04805970</nct_id>
  </id_info>
  <brief_title>REsearching Covid-19 Outcomes in Diabetes (RECODE)</brief_title>
  <acronym>RECODE</acronym>
  <official_title>REsearching Covid-19 Outcomes in Diabetes (RECODE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Institute for Metabolism and Diabetes, Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translational Research Institute for Metabolism and Diabetes, Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to observe any changes that may occur to certain organs&#xD;
      following a confirmed diagnosis of COVID-19 in people with and without diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measure and characterize organ volume change in patients with and without diabetes through use of summary statistics.</measure>
    <time_frame>1 year</time_frame>
    <description>Patients recovering from the COVID-19 disease</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Covid19</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Patients with and without diabetes who were previously diagnosed with COVID-19</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who were initially hospitalized with laboratory-confirmed SARS-CoV-2 infection&#xD;
        [COVID-19 disease], who are no-longer considered infectious by approved bioassay&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For Type 2 Diabetes (T2D)&#xD;
&#xD;
          1. Male or female 18 years of age and older willing and able to give informed consent to&#xD;
             participate in the study&#xD;
&#xD;
          2. Confirmed diagnosis of SARS-CoV-2 RNA via a polymerase chain reaction (PCR) assay&#xD;
             (having been discharged at least 2 months from hospital but not greater than 6&#xD;
             months).&#xD;
&#xD;
          3. Diagnosis of T2D according to American Diabetes Association (ADA) criteria.&#xD;
&#xD;
          4. Must have access to a computer/laptop or a modern (no more than 3-4 years old) smart&#xD;
             phone/tablet for cognitive assessments.&#xD;
&#xD;
        For participant without Type 2 Diabetes (T2D)&#xD;
&#xD;
          1. Male or female 18 years of age and older willing and able to give informed consent to&#xD;
             participate in the study&#xD;
&#xD;
          2. Confirmed diagnosis of SARS-CoV-2 RNA via a polymerase chain reaction (PCR) assay&#xD;
             (having been discharged at least 2 months from hospital but not greater than 6&#xD;
             months).&#xD;
&#xD;
          3. Must have access to a computer/laptop or a modern (no more than 3-4 years old) smart&#xD;
             phone/tablet for cognitive assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Symptoms of active respiratory viral infection:&#xD;
&#xD;
               1. high temperature (over 37.8°C/100.4°F)&#xD;
&#xD;
               2. cough (consistent for over an hour; 3 or more episodes in 24 hours)&#xD;
&#xD;
          2. Any history of Type I diabetes&#xD;
&#xD;
          3. The participant may not enter the study with any known contraindication to magnetic&#xD;
             resonance imaging including&#xD;
&#xD;
               1. Pregnancy, lactation or 6 months postpartum from the scheduled date of collection&#xD;
&#xD;
               2. Metal implants (pacemaker, aneurysm clips) based on Investigator's judgment at&#xD;
                  Screening&#xD;
&#xD;
               3. Unable to participate in MRI assessments due to physical limitations of equipment&#xD;
                  tolerances (e.g. MRI bore size) based on Investigator's judgment at Screening&#xD;
&#xD;
               4. Unable to tolerate MRI imaging or claustrophobia&#xD;
&#xD;
          4. Any condition, including a significant underlying disease or disorder which, in the&#xD;
             opinion of the investigator, may put the participant at risk by participating in the&#xD;
             study or limit the participant's ability to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Pratley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AdventHealth Orlando</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruitment Department</last_name>
    <phone>407-303-7100</phone>
    <email>Fh.tri.recruitment@adventhealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AdventHealth Translational Research Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Recruitment Department</last_name>
      <phone>407-303-7100</phone>
      <email>Fh.tri.recruitment@adventhealth.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

